에이프로젠

007460KOSPI의약품 제조업

55.8 / 100

Reference Date: 2026-07-24

Financial Score13.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure15.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly down 4.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen operates major businesses in hardfacing, steel sales, nuclear insulation, pharmaceuticals, and biopharmaceuticals, maintaining a leading position in the domestic hardfacing market. The biopharmaceutical division focuses on developing biosimilars and new drugs, successfully selling Remicade biosimilars in the Japanese market.

Number of Employees

311people

Average Salary

52.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

0.12Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE

-31.28Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

16.33Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼10.9% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.6% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
앱튼, 지피씨알 1차 투자 완료… CAR-T·비만치료제 신사업 본격화
에이프로젠 자회사 앱튼의 신규 투자로 CAR-T 및 비만치료제 분야에서의 혁신적 성장 기대.
Positive
앱튼, 지피씨알에 100억원 투자…최대주주 오른다
에이프로젠 자회사 앱튼의 100억원 투자로 지피씨알이 최대주주로 부상하며 기업 가치 상승 기대.
Positive
앱튼, 지피씨알 최대주주 등극…카티부스터 플랫폼 확보
앱튼의 지피씨알 인수로 에이프로젠 자회사의 핵심 기술 확보 및 시장 지배력 강화.

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 2,310Won52-week high 6,76052-week low 280

1-month return2.0Point

1m -4.55% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

15 totalPositive 5Neutral 10Negative 0

Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-07-23
Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral[기재정정]주식매수선택권부여에관한신고2026-07-16
Positive주요사항보고서(유상증자결정)(자회사의 주요경영사항)2026-07-14
Neutral주요사항보고서(전환사채권발행결정)2026-07-13